Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Keech C, Glenn GM, Albert G, et al. First-in-human trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. DOI:

Supplementary Appendix to Manuscript Entitled

**First-in-human trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine**

**Table of Contents**

[NVX-CoV2373 Study Team Members 3](#_Toc47374190)

[Supplemental Methods: 4](#_Toc47374191)

[Vaccination Pause Rules 4](#_Toc47374192)

[RT-PCR Testing Assays 5](#_Toc47374193)

[Immunologic Assay Method Details 5](#_Toc47374194)

[Convalescent Sera Description 7](#_Toc47374195)

[Table S1. Characteristics of COVID-19 patients providing convalescent sera for comparative analyses 8](#_Toc47374196)

[Standard Toxicity Criteria and Adverse Events of Special Interest 9](#_Toc47374197)

[Table S2. Toxicity grading scales for solicited local and systemic adverse events. 9](#_Toc47374198)

[Table S3. Adverse events of special interest relevant to COVID-19.\* 10](#_Toc47374199)

[Table S4. Potential immune-mediated medical conditions. 11](#_Toc47374200)

[Table S5. Toxicity grading scales for clinical laboratory abnormalities. 12](#_Toc47374201)

[Table S6. Toxicity grading scale for vital sign abnormalities. 13](#_Toc47374202)

[Supplemental Study Results: 13](#_Toc47374203)

[Supplemental Figures and Tables: 14](#_Toc47374204)

[Figure S1. Consort Flow Diagram. 14](#_Toc47374205)

[Table S7. Percentage of subjects experiencing solicited local and systemic adverse events by symptom, vaccination dose, vaccine group, and maximum toxicity grade.\* 15](#_Toc47374206)

[Table S8. Number and percentages of subjects experiencing a grade 2 or higher acute safety laboratory toxicity.\* 20](#_Toc47374207)

[Table S9. Treatment-emergent adverse events by system organ class and preferred term reported in 1% or more participants in the total group.\* 26](#_Toc47374208)

[Table S10. Geometric mean titer IgG responses to NVX-CoV2373 with or without Matrix-M1 adjuvant in participants and compared to cconvalescent serum specimens. 27](#_Toc47374209)

[Table S11. Geometric mean titer neutralizing antibody responses to NVX-CoV2373 with or without Matrix-M1 adjuvant in participants and compared to convalescent serum specimens. 29](#_Toc47374210)

# NVX-CoV2373 Study Team Members

The NVX-CoV2373 clinical trial was a collective group effort across multiple institutions and locations. Below is a list of sites and staff that significantly contributed to the implementation and conduct of the Phase 1 part of the NVX-CoV2373-2019nCoV-101 clinical trial.

Baylor College of Medicine, Houston, TX: Letisha Oduwa Aideyan, Laura S. Angelo, Vasanthi Avadhanula, Nanette Bond, Sonia Fragoso, Obinna Iwuchukwu, Lauren Maurer, Trevor McBride, Erin Griffin Nicholson, Kirtida D. Patel, Yolanda Joette Rayford, Patricia Santarcangelo, Xunyan Ye.

Novavax, Inc., Gaithersburg, MD and Novavax AB, Uppsala, Sweden: Jenny Reimer, PhD, Linda Stertman, Brian Webb.

Nucleus Network Pty Ltd, Melbourne, Victoria, Australia: Jemma Evans, Jessica Faggian, Biljana Georgievska, Kenia Krauer, Kaman Li, Tristan Morujao, Sougal Mousavi, My Trang VO.

University of Maryland School of Medicine, Baltimore, MD: Holly L. Hammond, Krystal L Matthews.

# Supplemental Methods:

## Vaccination Pause Rules

Adverse events meeting any one of the following criteria will result in a hold being placed on subsequent vaccinations pending further review by the safety monitoring committee (SMC):

* Any SAE attributed to vaccine.
* Any toxicity grade 3 (severe) solicited single AE term occurring in ≥ 7 participants across any single SARS-CoV-2 rS construct following vaccination (first and second vaccinations to be assessed separately).
* Toxicity grade 3 (severe) solicited single prespecified laboratory value occurring in ≥ 7 participants across any single SARS-CoV-2 rS construct following injection (first and second vaccinations to be assessed separately). Prespecified laboratory values to be evaluated include creatinine, alanine aminotransferase, aspartate aminotransferase, bilirubin, hemoglobin, complete white blood count, and platelets.
* Any grade 3 (severe) unsolicited single AE preferred term for which the investigator assesses as related which occurs in ≥ 7 participants across any single SARS-CoV-2 rS construct, within 49 days following vaccination (first).

The sponsor, along with medical monitor, may request an SMC review for any safety concerns that may arise in the trial and not associated with any specific pause rule.

## RT-PCR Testing Assays

Real-Time Polymerase Chain Reaction (RT-PCR) for detection of SARS-CoV-2 RNA was performed by 360biolabs (Melbourne, Victoria, Australia) using the laboratory assays: TaqPath COVID-19 RT PCR combo kit (Thermo Fisher Scientific) and Anti-SARS-CoV-2 IgG ELISA kit (EUROIMMUN). The TaqPath kit provides the primer/probes sets that specifically target three different SARS-CoV-2 genes: ORF1ab, Nucleocapsid (N) and Spike (S). In addition, the kit also includes an MS2 (bacteriophage) control that is used as an extraction control. The assay kit can detect SARS-CoV-2 RNA from 1x107 copies/reaction to 10 copies/reaction.

## Immunologic Assay Method Details

SARS-CoV-2 Spike Protein Serum IgG ELISA (performed at Novavax Clinical Immune Laboratory (Gaithersburg, MD). SARS-CoV-2 rS protein (NVX-CoV2373) was immobilized onto the surface of the 96-well microtiter plate wells (100 µL per well) by direct adsorption for 15 to 96 hours at 2°C to 8°C at a concentration of 1 µg/mL in PBS. Plates were washed 3 times with 300 µL/well PBST, blocked with 300 µL blocking buffer for 1-1.5 hours at 24°C ± 2°C. Diluted reference standard (2-fold dilution series of 12 dilutions starting 1:1000) and human serum samples (3-fold dilution series of 12 dilutions) in assay buffer (1% milk in PBS) starting at 1:100 dilution are then added in duplicate (100 µL per well) to the SARS-CoV-2 rS protein-coated wells and any specific antibodies are allowed to complex with the coated antigen for 2 hours at 24°C ± 2°C. Plates are washed 2 times with 300 µL/well PBST. Antibodies bound to the SARS-CoV-2 rS protein are then detected using a horseradish peroxidase (HRP) conjugate goat anti-human IgG antibody diluted 1: 2000 (Southern Biotech cat no. 2040-05) incubated for 1 hour ± 10 minutes at 24°C ± 2°C, washed 3 times with 300 µL/well PBST, and a colorimetric signal generated by addition of 100 µL per well 3, 3′,5,5′-tetramethylbenzidine (TMB) chromogenic substrate for 10 minutes ± 2 minutes at 24°C ± 2°C. After incubation was complete, the TMB reaction was stopped with 100 µL per well of TMB Stop solution. The absorbance was measured at 450 nm using a Molecular Device 96-well plate reader. When binding reagents (coated antigen and secondary antibody) are in excess, the optical density (OD) of the chromogenic substrate at endpoint is proportional to the quantity of anti-SARS-CoV-2 rS IgG present in the serum sample. The total anti-SARS-CoV-2 S protein IgG antibody level in a serum sample was quantitated in ELISA unit, EU/mL, by comparison to a reference standard curve. The results were analyzed by SoftMax Pro software using 4-PL curve fit. Assay included control plates comprising of positive controls and negative control.

SARS-CoV-2 Microneutralization Assay1-3(performed at the University of Maryland School of Medicine, Baltimore, MD). All serum samples were heat inactivated at 56°C for 30 minutes to remove complement and allowed to equilibrate to room temperature prior to processing for neutralization titer. Samples were diluted in duplicate to an initial dilution of 1:5 or 1:10 followed by 1:2 serial dilutions (vaccinated sample) or 1:3 serial dilutions (convalescent samples), resulting in a 12-dilution series with each well containing 100 µL. All dilutions were performed in DMEM (Quality Biological), supplemented with 10% (v/v) fetal bovine serum (heat inactivated, Sigma), 1% (v/v) penicillin/streptomycin (Gemini Bio-products), and 1% (v/v) L-glutamine (2 mM final concentration, Gibco). Dilution plates were then transported into the BSL-3 laboratory and 100 µL of diluted SARS‑CoV‑2 inoculum was added to each well to result in a multiplicity of infection (MOI) of 0.01 upon transfer to 96-well titer plates. A non-treated, virus-only control and a mock infection control were included on every plate. The sample/virus mixture was then incubated at 37°C (5.0% CO2) for 1 hour before transferring to 96-well titer plates with confluent VeroE6 cells. Titer plates were incubated at 37°C (5.0% CO2) for 72 hours, followed by cytopathic effect (CPE) determination for each well in the plate. The first sample dilution to show CPE was reported as the minimum sample dilution required to neutralize > 99% of the concentration of SARS-CoV-2 tested (neut99), expressed on the figures as 100%.

Cellular Immune Responses Assessed by Polyfunctional CD4+ T-cell Responses with Intracellular Cytokine Staining (ICCS) Analysis. Human peripheral blood mononuclear cells (PBMCs) were cultured overnight after thawing. Cells with a viability > 85% proceeded to the following assays. Human PBMCs were cultured in 96-well U-bottom plates at a density of 1-2 x 106 cells/well and treated with the recombinant spike (S) protein (NVX-CoV2373), PMA + Ionomycin (a positive control for T-cell activation), or medium only (negative control). After incubation at 37°C for 6 hours in the presence of BD GolgiPlug™ and BD GolgiStop™ (BD Biosciences, San Jose, CA) for the last 4 hours of culturing, cells were labelled for surface markers (CD3, CD4, CD8 [BD Biosciences]) and the LIVE/DEAD® indicator dye (Life Technologies, NY) was added. The intracellular cytokines were detected by antibodies specific for T helper 1 (Th1) cytokines interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), and interleukin (IL)-2; T helper 2 (Th2) cytokines IL-5 and IL-13 (BD Biosciences). The samples were processed using a LSR-Fortessa flow cytometer (Becton Dickinson, San Jose, CA). Data were analyzed using FlowJo software version Xv10 (Tree Star Inc., Ashland, OR). Data shown were gated on live CD4+ T-cell population.

## Convalescent Sera Description

Convalescent sera were collected from 32 adults with PCR-confirmed asymptomatic to severe symptoms of COVID-19 from Baylor College of Medicine (Houston, TX). The serum samples were provided to Novavax through a Master Trial Agreement, and all participants in this serology study provided written informed consent, with approval from the Institutional Review Board. These samples were tested using the same assays (anti-spike IgG ELISA and MN IC>99) as those in the NVX-CoV2373 Phase 1 trial 2019nCoV-101. MN IC>99 was run on 32 samples at the University of Maryland School of Medicine and anti-spike IgG ELISA analysis was run on 29 samples at the Novavax Clinical Immune Laboratory (Gaithersburg, MD), with the remaining samples no longer available at the time of the respective analyses. Demographic and COVID‑19 clinical characteristics of the patient samples are summarized in Table S1. The majority of COVID-19 patients were treated on an outpatient basis.

### Table S1. Characteristics of COVID-19 patients providing convalescent sera for comparative analyses

|  |  |  |
| --- | --- | --- |
| **Characteristics** | **Anti-Spike IgG ELISA****(N = 29)** | **MN IC>99****(N = 32)** |
| Age range, n (%) |
| 18-49 years | 18 (62.1%) | 20 (62.1%) |
| 50-64 years | 8 (27.6%) | 9 (28.1%) |
| 65-79 years | 3 (10.3%) | 3 ( 9.4%) |
| Male sex, n (%) | 17 (58.6%) | 18 (56.3%) |
| Median days since initial viral testing (IQR) | 19 (11-26) | 19 (9-25) |
| COVID-19 illness severity† |
| Asymptomatic/Exposed, n (%) | 3 (10.3%) | 3 ( 9.4%) |
| Outpatient-treated, n (%) | 22 (75.9%) | 25 (78.1%) |
| Hospitalized, n (%) | 4 (13.8%) | 4 (12.5%) |

COVID-19 denotes coronavirus disease 2019, IQR interquartile range, MN IC>99 microneutralization assay with an inhibitory concentration > 99%.

\* COVID-19 illness severity categories 1) Asymptomatic/Exposed: sample collected from contact/exposure assessment of patient; 2) Outpatient-treated: sample collected from outpatient discharged from emergency department with constellation of symptoms including fever, chills, cough, shortness of breath, chest pain, congestion, sore throat, muscle/joint pain, headache, fatigue, loss of smell, loss of taste, dizziness, diarrhea, abdominal pain, and nausea (symptom duration average of 15 days; and 3) Hospitalized: sample collected from patient hospitalized including intensive care unit supportive measures (symptom duration average of 30 days).

## Standard Toxicity Criteria and Adverse Events of Special Interest

|  |
| --- |
| Table S2. Toxicity grading scales for solicited local and systemic adverse events. |
| Local Reaction to Injectable Product | Mild(Grade 1) | Moderate (Grade 2) | Severe(Grade 3) | Potentially Life Threatening (Grade 4) |
| Pain | Does not interfere with activity | Repeated use of nonnarcotic pain reliever >24 hours or interferes with activity | Any use of narcotic pain reliever or prevents daily activity | ER visit or hospitalization |
| Tenderness | Mild discomfort to touch | Discomfort with movement | Significant discomfort at rest | ER visit or hospitalization |
| Erythema/redness\* | 2.5 − 5 cm | 5.1 − 10 cm | >10 cm | Necrosis or exfoliative dermatitis |
| Induration/swelling† | 2.5 − 5 cm and does not interfere with activity | 5.1 − 10 cm or interferes with activity | >10 cm or prevents daily activity | Necrosis |
| **Systemic (General)** | **Mild(Grade 1)** | **Moderate (Grade 2)** | **Severe(Grade 3)** | **Potentially Life Threatening (Grade 4)** |
| Fever‡ (°C) (°F) | 38.0 − 38.4100.4 − 101.1 | 38.5 − 38.9101.2 − 102.0 | 39.0 − 40102.1 − 104 | >40>104 |
| Nausea/vomiting  | No interference with activity or 1 − 2 episodes/24 hours  | Some interference with activity or >2 episodes/24 hours  | Prevents daily activity, or requires outpatient IV hydration | ER visit or hospitalization for hypotensive shock  |
| Headache  | No interference with activity  | Repeated use of nonnarcotic pain reliever >24 hours or some interference with activity  | Significant; any use of narcotic pain reliever or prevents daily activity  | ER visit or hospitalization |
| Fatigue/Malaise | No interference with activity  | Some interference with activity  | Significant; prevents daily activity  | ER visit or hospitalization |
| Myalgia | No interference with activity  | Some interference with activity  | Significant; prevents daily activity  | ER visit or hospitalization |
| Arthralgia  | No interference with activity  | Some interference with activity  | Significant; prevents daily activity  | ER visit or hospitalization |
| \* In addition to grading the measured local reaction at the greatest single diameter, the measurement should be recorded as a continuous variable. † Induration/swelling should be evaluated and graded using the functional scale as well as the actual measurement.‡ Oral temperature; no recent hot or cold beverages.Source (DHHS 2007).4  |

| Table S3. Adverse events of special interest relevant to COVID-19.\* |
| --- |
| **Body System** | **Diagnoses** |
| Immunologic  | Enhanced disease following immunization, cytokine release syndrome related to COVID-19 disease†, multisystem inflammatory syndrome in children (MIS-C) |
| Respiratory | Acute respiratory distress syndrome (ARDS) |
| Cardiac | Acute cardiac injury including: * Microangiopathy
* Heart failure and cardiogenic shock
* Stress cardiomyopathy
* Coronary artery disease
* Arrhythmia
* Myocarditis, pericarditis
 |
| Hematologic | Coagulation disorder* Deep vein thrombosis
* Pulmonary embolus
* Cerebrovascular stroke
* Limb ischemia
* Hemorrhagic disease
* Thrombotic complications
 |
| Renal | Acute kidney injury  |
| Gastrointestinal | Liver injury  |
| Neurologic | Guillain Barré Syndrome, anosmia, ageusia, meningoencephalitis |
| Dermatologic | Chilblain-like lesions, single organ cutaneous vasulitis, erythema multiforme |
| \* COVID-19 disease manifestations associated with more severe presentation and decompensation with consideration of enhanced disease potential. The current listing is based on Safety Platform for Emergency Vaccines (SPEAC) D2.3 Priority List of Adverse Events of Special Interest: COVID-19.5† Cytokine Release Syndrome related to COVID-19 disease is a disorder characterized by nausea, headache, tachycardia, hypotension, rash, and/or shortness of breath.6  |
|  |

| Table S4. Potential immune-mediated medical conditions. |
| --- |
| **Categories** | **Diagnoses (as MedDRA Preferred Terms)** |
| Neuroinflammatory Disorders: | Acute disseminated encephalomyelitis (including site specific variants: eg, non-infectious encephalitis, encephalomyelitis, myelitis, myeloradiculomyelitis), cranial nerve disorders including paralyses/paresis (eg, Bell’s palsy), generalized convulsion, Guillain-Barre syndrome (including Miller Fisher syndrome and other variants), immune‑mediated peripheral neuropathies and plexopathies (including chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy and polyneuropathies associated with monoclonal gammopathy), myasthenia gravis, multiple sclerosis, narcolepsy, optic neuritis, transverse myelitis, uveitis |
| Musculoskeletal and Connective Tissue Disorders: | Antisynthetase syndrome, dermatomyositis, juvenile chronic arthritis (including Still’s disease), mixed connective tissue disorder, polymyalgia rheumatic, polymyositis, psoriatic arthropathy, relapsing polychondritis, rheumatoid arthritis, scleroderma (including diffuse systemic form and CREST syndrome), spondyloarthritis (including ankylosing spondylitis, reactive arthritis [Reiter's Syndrome] and undifferentiated spondyloarthritis), systemic lupus erythematosus, systemic sclerosis, Sjogren’s syndrome  |
| Vasculidities: | Large vessels vasculitis (including giant cell arteritis such as Takayasu's arteritis and temporal arteritis), medium sized and/or small vessels vasculitis (including polyarteritis nodosa, Kawasaki's disease, microscopic polyangiitis, Wegener's granulomatosis, Churg–Strauss syndrome [allergic granulomatous angiitis], Buerger’s disease [thromboangiitis obliterans], necrotizing vasculitis and anti-neutrophil cytoplasmic antibody [ANCA] positive vasculitis [type unspecified], Henoch-Schonlein purpura, Behcet's syndrome, leukocytoclastic vasculitis)  |
| Gastrointestinal Disorders: | Crohn’s disease, celiac disease, ulcerative colitis, ulcerative proctitis |
| Hepatic Disorders:  | Autoimmune hepatitis, autoimmune cholangitis, primary sclerosing cholangitis, primary biliary cirrhosis |
| Renal Disorders: | Autoimmune glomerulonephritis (including IgA nephropathy, glomerulonephritis rapidly progressive, membranous glomerulonephritis, membranoproliferative glomerulonephritis, and mesangioproliferative glomerulonephritis |
| Cardiac Disorders: | Autoimmune myocarditis/cardiomyopathy |
| Skin Disorders: | Alopecia areata, psoriasis, vitiligo, Raynaud’s phenomenon, erythema nodosum, autoimmune bullous skin diseases (including pemphigus, pemphigoid and dermatitis herpetiformis), cutaneous lupus erythematosus, morphoea, lichen planus, Stevens-Johnson syndrome, Sweet’s syndrome  |
| Hematologic Disorders: | Autoimmune hemolytic anemia, autoimmune thrombocytopenia, antiphospholipid syndrome, thrombocytopenia |
| Metabolic Disorders: | Autoimmune thyroiditis, Grave’s or Basedow’s disease, Hashimoto thyroiditis\*, diabetes mellitus type 1, Addison’s disease |
| Other Disorders: | Goodpasture syndrome, idiopathic pulmonary fibrosis, pernicious anemia, sarcoidosis |
| \* For Hashimoto thyroiditis: new onset only.  |

|  |
| --- |
| Table S5. Toxicity grading scales for clinical laboratory abnormalities. |
| Serum Chemistry and Hematology | Mild(Grade 1) | Moderate(Grade 2) | Severe(Grade 3) | Potentially Life Threatening(Grade 4)a |
| Sodium – hyponatremia (mEq/L)  | 132 – 134 | 130 – 131 | 125 – 129 | <125 |
| Sodium – hypernatremia (mEq/L) | 144 – 145 | 146 – 147 | 148 – 150 | >150 |
| Potassium – hyperkalemia (mEq/L) | 5.1 – 5.2 | 5.3 – 5.4 | 5.5 – 5.6 | >5.6 |
| Potassium – hypokalemia (mEq/L) | 3.5 – 3.6 | 3.3 – 3.4 | 3.1 – 3.2 | <3.1 |
| Glucose – hyperglycemiaRandom (mg/dL) *(mmol/L*)c  | 116 to 160 *6.44 to <8.89*  | >160 to 250*8.89 to <13.89*  | >250 to 500*13.89 to <27.75*  | ≥500≥*27.75*  |
| Urea (ie, BUN) (mg/dL) | 23 – 26 | 27 – 31 | >31 | Requires dialysis |
| Creatinine (mg/dL)b | 1.5 – 1.7 | 1.8 – 2.0 | 2.1 – 2.5 | >2.5 or requires dialysis |
| Total protein – hypoproteinemia (g/dL)  | 5.5 – 6.0 | 5.0 – 5.4 | <5.0 | – |
| Liver function tests – ALT, AST; increase by factorb | 1.1 – 2.5 × ULN | 2.6-5.0 × ULN | 5.1 – 10 × ULN | >10 × ULN |
| Total bilirubin – when accompanied by any increase in liver function test; increase by factorb | 1.1 – 1.25 × ULN | 1.26 – 1.5 × ULN | 1.51 – 1.75 × ULN | >1.75 × ULN |
| Total bilirubin – when liver function test is normal; increase by factorb | 1.1 – 1.5 × ULN | 1.6 – 2.0 × ULN | 2.0 – 3.0 × ULN | >3.0 × ULN |
| Hemoglobin (Female) (g/dL)b | 11.0 – 12.0 | 9.5 – 10.9 | 8.0 – 9.4 | <8.0 |
| Hemoglobin (Female) change from baseline value (g/dL) | Any decrease – 1.5 | 1.6 – 2.0 | 2.1 – 5.0 | >5.0 |
| Hemoglobin (Male) (g/dL)b | 12.5 – 13.5 | 10.5 – 12.4 | 8.5 – 10.4 | <8.5 |
| Hemoglobin (Male) change from baseline value (g/dL) | Any decrease – 1.5 | 1.6 – 2.0 | 2.1 – 5.0 | >5.0 |
| WBC increase (cell/mm3)b | 10,800 – 15,000 | 15,001 – 20,000 | 20,001 – 25,000 | >25,000 |
| WBC decrease (cell/mm3)b | 2,500 – 3,500 | 1,500 – 2,499 | 1,000 – 1,499 | <1,000 |
| Platelets decreased (cell/mm3)b | 125,000 – 140,000 | 100,000 – 124,000 | 25,000 – 99,000 | <25,000 |
| Notes: The laboratory values provided in the table serve as guidelines and are dependent upon institutional normal parameters. Institutional normal reference ranges should be provided to demonstrate that they are appropriate. Adjustments will be made for formal toxicity grading based on the local parameter and overlap with the above FDA ranges. The clinical signs or symptoms associated with laboratory abnormalities might result in characterization of the laboratory abnormalities as Potentially Life Threatening (grade 4). For example, a low sodium value that falls within a grade 3 parameter (125-129 mE/L) should be recorded as a grade 4 hyponatremia event if the subject had a new seizure associated with the low sodium value.1. Values to be included in vaccination pause rules (highlighted in light grey) for Part 1 of the study.
2. DAIDS toxicity scoring scale.

Source (DAIDS 2017; DHHS 2007)4,6 |

|  |
| --- |
| Table S6. Toxicity grading scale for vital sign abnormalities. |
| Vital Sign Abnormalities | Mild(Grade 1)  | Moderate(Grade 2)  | Severe(Grade 3)  | Potentially Life Threatening(Grade 4)  |
| Tachycardia (bpm)  | 101 – 115  | 116 – 130  | >130  | ER visit or hospitalization for arrhythmia  |
| Bradycardia (bpm)a  | 50 – 54  | 45 – 49  | <45  | ER visit or hospitalization for arrhythmia  |
| Hypertension (systolic) (mm Hg)  | 141 – 150  | 151 – 155  | >155  | ER visit or hospitalization for malignant hypertension  |
| Hypertension (diastolic) (mm Hg) | 91 – 95  | 96 – 100  | >100  | ER visit or hospitalization for malignant hypertension  |
| Hypotension (systolic) (mm Hg) | 85 – 89  | 80 – 84  | <80  | ER visit or hospitalization for hypotensive shock  |
| Respiratory Rate(breaths per minute) | 17 – 20  | 21 – 25 | >25  | Intubation  |
| Note: Subject should be at rest for all vital sign measurements. 1. When resting heart rate is between 60 – 100 bpm. Use clinical judgement when characterizing bradycardia among some healthy subject populations (eg, conditioned athletes).

Source (DHHS 2007).4 |

# Supplemental Study Results:

*Acute safety laboratory or vital sign grade 2 or higher toxicity*

Laboratory abnormalities of grade 2 or higher occurred in very few participants and were not associated with any clinical manifestations or worsening with repeat vaccination (Table S8). The most frequent observations were changes in hemoglobin from baseline, with the majority of subjects having absolute hemoglobins in the normal range and all showing resolution. All laboratory indices were < grade 1 at the time of this report. Vital signs remained stable immediately following vaccination and at all visits.

*Unsolicited adverse events*

Unsolicited adverse events (Table S9) were mainly mild in nature and similar between active vaccine groups. A slight decrease was observed after second vaccination but attributed to a shorter duration of observation. Outside of administrative site conditions and safety laboratory monitoring, the most common adverse events were under the system organ class of Infections and Infestations. During this reporting period, six cases of suspected COVID-19 were investigated. All had negative PCR results. In addition, all participants had negative PCR at Day 35. Related events were mainly mild (n=19), with only three classified as moderate (including one receiving placebo). A dose relationship was not observed.

# Supplemental Figures and Tables:

### Figure S1. Consort Flow Diagram.



| Table S7. Percentage of subjects experiencing solicited local and systemic adverse events by symptom, vaccination dose, vaccine group, and maximum toxicity grade.\* |
| --- |
| **Symptom** | **Vaccination Dose** | **Vaccine Group†** | **N** | **% Grade 0****(None)** | **% Grade 1****(Mild)** | **% Grade 2****(Moderate)** | **% Grade 3****(Severe)** | **% Grade 4****(Life-threatening)** |
| Any solicited local AE | 1 | ABCCSDDSE | 0/ 025/ 05/505/5025/5025/5025/50 | 232526 325 326 | 69.668.030.8040.0019.2 | 30.428.057.7100.044.0100.069.2 | 04.011.5016.0011.5 | 0000000 | 0000000 |
| 2 | ABCCSDDSE | 0/ 025/ 05/505/5025/5025/500/ 0 | 212526 324 326 | 81.076.07.733.320.8084.6 | 19.024.057.733.345.8100.015.4 | 0034.633.329.200 | 00004.200 | 0000000 |
| Pain | 1 | ABCCSDDSE | 0/ 025/ 05/505/5025/5025/5025/50 | 232526 325 326 | 87.076.061.533.356.033.346.2 | 13.024.038.566.744.066.753.8 | 0000000 | 0000000 | 0000000 |
| 2 | ABCCSDDSE | 0/ 025/ 05/505/5025/5025/500/ 0 | 212526 324 326 | 90.592.042.333.337.533.388.5 | 9.58.050.066.750.066.711.5 | 007.7012.500 | 0000000 | 0000000 |
| Erythema | 1 | ABCCSDDSE | 0/ 025/ 05/505/5025/5025/5025/50 | 232526 325 326 | 100.0100.0100.066.7100.0100.096.2 | 00033.3003.8 | 0000000 | 0000000 | 0000000 |
| 2 | ABCCSDDSE | 0/ 025/ 05/505/5025/5025/500/ 0 | 212526 324 326 | 95.296.092.366.7100.0100.096.2 | 4.84.03.80003.8 | 003.833.3000 | 0000000 | 0000000 |
| Swelling | 1 | ABCCSDDSE | 0/ 025/ 05/505/5025/5025/5025/50 | 232526 325 326 | 100.0100.0100.0100.0100.0100.0100.0 | 0000000 | 0000000 | 0000000 | 0000000 |
| 2 | ABCCSDDSE | 0/ 025/ 05/505/5025/5025/500/ 0 | 212526 324 326 | 100.096.096.2100.091.7100.0100.0 | 04.0008.300 | 003.80000 | 0000000 | 0000000 |
| Tenderness | 1 | ABCCSDDSE | 0/ 025/ 05/505/5025/5025/5025/50 | 232526 325 326 | 69.680.034.6048.0038.5 | 30.416.053.8100.036.0100.050.0 | 04.011.5016.0011.5 | 0000000 | 0000000 |
| 2 | ABCCSDDSE | 0/ 025/ 05/505/5025/5025/500/ 0 | 212526 324 326 | 90.588.019.233.320.8092.3 | 9.512.057.733.345.8100.07.7 | 0023.133.329.200 | 00004.200 | 0000000 |
| Any solicited systemic AE | 1 | ABCCSDDSE | 0/ 025/ 05/505/5025/5025/5025/50 | 232526 325 326 | 60.952.053.833.344.033.342.3 | 30.440.042.366.724.066.746.2 | 8.78.03.8028.007.7 | 00004.003.8 | 0000000 |
| 2 | ABCCSDDSE | 0/ 025/ 05/505/5025/5025/500/ 0 | 212526 324 326 | 66.764.034.6025.0073.1 | 19.020.038.5100.033.3100.023.1 | 9.58.019.2033.300 | 4.88.07.708.303.8 | 0000000 |
| Joint pain/ arthralgia | 1 | ABCCSDDSE | 0/ 025/ 05/505/5025/5025/5025/50 | 232526 325 326 | 95.796.096.2100.092.066.784.6 | 4.34.03.808.033.37.7 | 0000007.7 | 0000000 | 0000000 |
| 2 | ABCCSDDSE | 0/ 025/ 05/505/5025/5025/500/ 0 | 212526 324 326 | 90.596.073.1100.087.566.796.2 | 4.8019.20033.30 | 4.803.804.200 | 04.03.808.303.8 | 0000000 |
| Fatigue | 1 | ABCCSDDSE | 0/ 025/ 05/505/5025/5025/5025/50 | 232526 325 326 | 82.684.069.2100.060.066.773.1 | 8.716.026.9028.033.315.4 | 8.703.8012.007.7 | 000003.8 | 0000000 |
| 2 | ABCCSDDSE | 0/ 025/ 05/505/5025/5025/500/ 0 | 212526 324 326 | 85.788.053.866.750.066.784.6 | 4.84.023.133.325.033.315.4 | 4.88.019.2016.700 | 4.803.808.300 | 0000000 |
| Malaise | 1 | ABCCSDDSE | 0/ 025/ 05/505/5025/5025/5025/50 | 232526 325 326 | 91.396.088.5100.072.066.784.6 | 4.34.011.5020.033.33.8 | 4.30008.007.7 | 0000003.8 | 0000000 |
| 2 | ABCCSDDSE | 0/ 025/ 05/505/5025/5025/500/ 0 | 212526 324 326 | 85.792.065.466.762.566.796.2 | 9.5023.133.312.533.33.8 | 4.88.011.5016.700 | 00008.300 | 0000000 |
| Temperature/ Fever | 1 | ABCCSDDSE | 0/ 025/ 05/505/5025/5025/5025/50 | 232526 325 326 | 100.0100.0100.0100.0100.0100.0100.0 | 0000000 | 0000000 | 0000000 | 0000000 |
| 2 | ABCCSDDSE | 0/ 025/ 05/505/5025/5025/500/ 0 | 212526 324 326 | 100.0100.0100.0100.095.8100.0100.0 | 00004.200 | 0000000 | 0000000 | 0000000 |
| Headache | 1 | ABCCSDDSE | 0/ 025/ 05/505/5025/5025/5025/50 | 232526 325 326 | 69.660.076.9100.068.033.376.9 | 21.736.019.2024.066.715.4 | 8.74.03.804.007.7 | 00004.000 | 0000000 |
| 2 | ABCCSDDSE | 0/ 025/ 05/505/5025/5025/500/ 0 | 212526 324 326 | 71.472.053.866.741.7100.080.8 | 23.816.038.533.341.7015.4 | 4.88.07.7016.703.8 | 04.000000 | 0000000 |
| Muscle pain/ Myalgia | 1 | ABCCSDDSE | 0/ 025/ 05/505/5025/5025/5025/50 | 232526 325 326 | 91.388.076.933.368.066.769.2 | 4.38.023.166.724.033.319.2 | 4.34.0008.0011.5 | 0000000 | 0000000 |
| 2 | ABCCSDDSE | 0/ 025/ 05/505/5025/5025/500/ 0 | 212526 324 326 | 85.792.053.8045.8096.2 | 4.88.030.8100.037.5100.03.8 | 9.5011.508.300 | 003.808.300 | 0000000 |
|  |
| Nausea or vomiting | 1 | ABCCSDDSE | 0/ 025/ 05/505/5025/5025/5025/50 | 232526 325 326 | 95.784.096.2100.096.0100.084.6 | 4.316.0000011.5 | 003.804.003.8 | 0000000 | 0000000 |
| 2 | ABCCSDDSE | 0/ 025/ 05/505/5025/5025/500/ 0 | 212526 324 326 | 100.092.092.3100.087.5100.0100.0 | 04.07.7012.500 | 0000000 | 04.000000 | 0000000 |

\* AE denotes adverse event, CS Group C sentinel participants, DS Group D sentinel participants, N number of participants assessed.

† Group A (placebo): 0 µg NVX-CoV2373/0 µg Matrix-M1 on first vaccination; 0 µg NVX-CoV2373/0 µg Matrix-M1 on second vaccination; Group B: 25 µg NVX-CoV2373/0 µg Matrix-M1 on first vaccination; 25 µg NVX-CoV2373/0 µg Matrix-M1 on second vaccination; Group C/CS: 5 µg NVX-CoV2373/50 µg Matrix-M1 on first vaccination; 5 µg NVX-CoV2373/50 µg Matrix-M1 on second vaccination; Group D/DS: 25 µg NVX-CoV2373/50 µg Matrix-M1 on first vaccination; 25 µg NVX-CoV2373/50 µg Matrix-M1 on second vaccination; and Group E: 25 µg NVX-CoV2373/50 µg Matrix-M1 on first vaccination; 0 µg NVX-CoV2373/0 µg Matrix-M1 on second vaccination.

| Table S8. Number and percentages of subjects experiencing a grade 2 or higher acute safety laboratory toxicity.\* |
| --- |
| **Grade 2 or Higher Laboratory Abnormality** | **Study Visit** | **Group A****0/0; 0/0**†**(N=23)** | **Group B****25/0; 25/0**†**(N=25)** | **Group C****5/50; 5/50**†**(N=26)** | **Group CS****5/50; 5/50**†**(N=3)** | **Group D****25/50; 25/50**†**(N=25)** | **Group DS****25/50; 25/50**†**(N=3)** | **Group E****25/50; 0/0**†**(N=26)** | **Total****(N=131)** |
| Hemoglobin |  |  |  |  |  |  |  |  |  |
|  | Baseline |  |  |  |  |  |  |  |  |
|  | Grade 0 | 23 (100.0) | 25 (100.0) | 24 ( 92.3) | 3 (100.0) | 24 ( 96.0) | 3 (100.0) | 26 (100.0) | 128 ( 97.7) |
|  | Grade 1 | 0 | 0 | 2 ( 7.7) | 0 | 1 ( 4.0) | 0 | 0 | 3 ( 2.3) |
|  | Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Day 7 |  |  |  |  |  |  |  |  |
|  | Grade 0 | 21 ( 91.3) | 23 ( 92.0) | 24 ( 92.3) | 3 (100.0) | 23 ( 92.0) | 3 (100.0) | 24 ( 92.3) | 121 ( 92.4) |
|  | Grade 1 | 1 ( 4.3) | 1 ( 4.0) | 2 ( 7.7) | 0 | 2 ( 8.0) | 0 | 1 ( 3.8) | 7 ( 5.3) |
|  | Grade 2 | 1 ( 4.3) | 0 | 0 | 0 | 0 | 0 | 0 | 1 ( 0.8) |
|  | Grade 3 | 0 | 1 ( 4.0) | 0 | 0 | 0 | 0 | 1 ( 3.8) | 2 ( 1.5) |
|  | Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Day 21 |  |  |  |  |  |  |  |  |
|  | Grade 0 | 19 ( 90.5) | 25 (100.0) | 25 ( 96.2) | 2 ( 66.7) | 23 ( 95.8) | 3 (100.0) | 25 ( 96.2) | 122 ( 95.3) |
|  | Grade 1 | 1 ( 4.8) | 0 | 0 | 0 | 1 ( 4.2) | 0 | 1 ( 3.8) | 3 ( 2.3) |
|  | Grade 2 | 1 ( 4.8) | 0 | 0 | 0 | 0 | 0 | 0 | 1 ( 0.8) |
|  | Grade 3 | 0 | 0 | 1 ( 3.8) | 1 ( 33.3) | 0 | 0 | 0 | 2 ( 1.6) |
|  | Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Day 28 |  |  |  |  |  |  |  |  |
|  | Grade 0 | 18 ( 85.7) | 22 ( 88.0) | 24 ( 92.3) | 3 (100.0) | 22 ( 88.0) | 3 (100.0) | 23 ( 88.5) | 115 ( 89.1) |
|  | Grade 1 | 2 ( 9.5) | 2 ( 8.0) | 2 ( 7.7) | 0 | 3 ( 12.0) | 0 | 2 ( 7.7) | 11 ( 8.5) |
|  | Grade 2 | 1 ( 4.8) | 0 | 0 | 0 | 0 | 0 | 0 | 1 ( 0.8) |
|  | Grade 3 | 0 | 1 ( 4.0) | 0 | 0 | 0 | 0 | 1 ( 3.8) | 2 ( 1.6) |
|  | Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  |
| Alanine aminotransferase |  |  |  |  |  |  |  |  |  |
|  | Baseline |  |  |  |  |  |  |  |  |
|  | Grade 0 | 23 (100.0) | 24 ( 96.0) | 24 ( 92.3) | 3 (100.0) | 23 ( 92.0) | 3 (100.0) | 24 ( 92.3) | 124 ( 94.7) |
|  | Grade 1 | 0 | 1 ( 4.0) | 2 ( 7.7) | 0 | 2 ( 8.0) | 0 | 2 ( 7.7) | 7 ( 5.3) |
|  | Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Day 7 |  |  |  |  |  |  |  |  |
|  | Grade 0 | 21 ( 91.3) | 21 ( 84.0) | 23 ( 88.5) | 3 (100.0) | 23 ( 92.0) | 3 (100.0) | 24 ( 92.3) | 118 ( 90.1) |
|  | Grade 1 | 2 ( 8.7) | 3 ( 12.0) | 2 ( 7.7) | 0 | 1 ( 4.0) | 0 | 2 ( 7.7) | 10 ( 7.6) |
|  | Grade 2 | 0 | 1 ( 4.0) | 0 | 0 | 1 ( 4.0) | 0 | 0 | 2 ( 1.5) |
|  | Grade 3 | 0 | 0 | 1 ( 3.8) | 0 | 0 | 0 | 0 | 1 ( 0.8) |
|  | Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Day 21 |  |  |  |  |  |  |  |  |
|  | Grade 0 | 21 (100.0) | 22 ( 88.0) | 21 ( 80.8) | 3 (100.0) | 22 ( 91.7) | 3 (100.0) | 25 ( 96.2) | 117 ( 91.4) |
|  | Grade 1 | 0 | 3 ( 12.0) | 5 ( 19.2) | 0 | 2 ( 8.3) | 0 | 1 ( 3.8) | 11 ( 8.6) |
|  | Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Day 28 |  |  |  |  |  |  |  |  |
|  | Grade 0 | 20 ( 95.2) | 22 ( 88.0) | 23 ( 88.5) | 3 (100.0) | 23 ( 92.0) | 3 (100.0) | 25 ( 96.2) | 119 ( 92.2) |
|  | Grade 1 | 0 | 3 ( 12.0) | 3 ( 11.5) | 0 | 2 ( 8.0) | 0 | 1 ( 3.8) | 9 ( 7.0) |
|  | Grade 2 | 1 ( 4.8) | 0 | 0 | 0 | 0 | 0 | 0 | 1 ( 0.8) |
|  | Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  |
| Aspartate aminotransferase |  |  |  |  |  |  |  |  |  |
|  | Baseline |  |  |  |  |  |  |  |  |
|  | Grade 0 | 23 (100.0) | 24 ( 96.0) | 25 ( 96.2) | 3 (100.0) | 25 (100.0) | 3 (100.0) | 25 ( 96.2) | 128 ( 97.7) |
|  | Grade 1 | 0 | 1 ( 4.0) | 1 ( 3.8) | 0 | 0 | 0 | 1 ( 3.8) | 3 ( 2.3) |
|  | Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Day 7 |  |  |  |  |  |  |  |  |
|  | Grade 0 | 21 ( 91.3) | 23 ( 92.0) | 24 ( 92.3) | 2 ( 66.7) | 23 ( 92.0) | 3 (100.0) | 25 ( 96.2) | 121 ( 92.4) |
|  | Grade 1 | 2 ( 8.7) | 1 ( 4.0) | 2 ( 7.7) | 1 ( 33.3) | 1 ( 4.0) | 0 | 1 ( 3.8) | 8 ( 6.1) |
|  | Grade 2 | 0 | 1 ( 4.0) | 0 | 0 | 1 ( 4.0) | 0 | 0 | 2 ( 1.5) |
|  | Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Day 21 |  |  |  |  |  |  |  |  |
|  | Grade 0 | 20 ( 95.2) | 22 ( 88.0) | 24 ( 92.3) | 2 ( 66.7) | 22 ( 91.7) | 3 (100.0) | 24 ( 92.3) | 117 ( 91.4) |
|  | Grade 1 | 1 ( 4.8) | 3 ( 12.0) | 2 ( 7.7) | 1 ( 33.3) | 2 ( 8.3) | 0 | 2 ( 7.7) | 11 ( 8.6) |
|  | Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Day 28 |  |  |  |  |  |  |  |  |
|  | Grade 0 | 20 ( 95.2) | 22 ( 88.0) | 26 (100.0) | 3 (100.0) | 24 ( 96.0) | 3 (100.0) | 24 ( 92.3) | 122 ( 94.6) |
|  | Grade 1 | 0 | 3 ( 12.0) | 0 | 0 | 1 ( 4.0) | 0 | 2 ( 7.7) | 6 ( 4.7) |
|  | Grade 2 | 1 ( 4.8) | 0 | 0 | 0 | 0 | 0 | 0 | 1 ( 0.8) |
|  | Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  |
| Sodium |  |  |  |  |  |  |  |  |  |
|  | Baseline |  |  |  |  |  |  |  |  |
|  | Grade 0 | 23 (100.0) | 25 (100.0) | 26 (100.0) | 3 (100.0) | 25 (100.0) | 3 (100.0) | 26 (100.0) | 131 (100.0) |
|  | Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Day 7 |  |  |  |  |  |  |  |  |
|  | Grade 0 | 22 ( 95.7) | 24 ( 96.0) | 26 (100.0) | 3 (100.0) | 25 (100.0) | 3 (100.0) | 26 (100.0) | 129 ( 98.5) |
|  | Grade 1 | 1 ( 4.3) | 1 ( 4.0) | 0 | 0 | 0 | 0 | 0 | 2 ( 1.5) |
|  | Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Day 21 |  |  |  |  |  |  |  |  |
|  | Grade 0 | 21 (100.0) | 24 ( 96.0) | 25 ( 96.2) | 3 (100.0) | 24 (100.0) | 2 ( 66.7) | 26 (100.0) | 125 ( 97.7) |
|  | Grade 1 | 0 | 1 ( 4.0) | 0 | 0 | 0 | 1 ( 33.3) | 0 | 2 ( 1.6) |
|  | Grade 2 | 0 | 0 | 1 ( 3.8) | 0 | 0 | 0 | 0 | 1 ( 0.8) |
|  | Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Day 28 |  |  |  |  |  |  |  |  |
|  | Grade 0 | 21 (100.0) | 25 (100.0) | 26 (100.0) | 3 (100.0) | 25 (100.0) | 3 (100.0) | 26 (100.0) | 129 (100.0) |
|  | Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  |
| Total bilirubin |  |  |  |  |  |  |  |  |  |
|  | Baseline |  |  |  |  |  |  |  |  |
|  | Grade 0 | 23 (100.0) | 22 ( 88.0) | 26 (100.0) | 3 (100.0) | 22 ( 88.0) | 3 (100.0) | 23 ( 88.5) | 122 ( 93.1) |
|  | Grade 1 | 0 | 3 ( 12.0) | 0 | 0 | 2 ( 8.0) | 0 | 2 ( 7.7) | 7 ( 5.3) |
|  | Grade 2 | 0 | 0 | 0 | 0 | 1 ( 4.0) | 0 | 1 ( 3.8) | 2 ( 1.5) |
|  | Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Day 7 |  |  |  |  |  |  |  |  |
|  | Grade 0 | 20 ( 87.0) | 23 ( 92.0) | 26 (100.0) | 2 ( 66.7) | 24 ( 96.0) | 3 (100.0) | 25 ( 96.2) | 123 ( 93.9) |
|  | Grade 1 | 3 ( 13.0) | 2 ( 8.0) | 0 | 1 ( 33.3) | 0 | 0 | 0 | 6 ( 4.6) |
|  | Grade 2 | 0 | 0 | 0 | 0 | 1 ( 4.0) | 0 | 1 ( 3.8) | 2 ( 1.5) |
|  | Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Day 21 |  |  |  |  |  |  |  |  |
|  | Grade 0 | 21 (100.0) | 22 ( 88.0) | 25 ( 96.2) | 2 ( 66.7) | 23 ( 95.8) | 3 (100.0) | 23 ( 88.5) | 119 ( 93.0) |
|  | Grade 1 | 0 | 3 ( 12.0) | 1 ( 3.8) | 1 ( 33.3) | 1 ( 4.2) | 0 | 2 ( 7.7) | 8 ( 6.3) |
|  | Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 ( 3.8) | 1 ( 0.8) |
|  | Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Day 28 |  |  |  |  |  |  |  |  |
|  | Grade 0 | 21 (100.0) | 22 ( 88.0) | 25 ( 96.2) | 2 ( 66.7) | 25 (100.0) | 3 (100.0) | 24 ( 92.3) | 122 ( 94.6) |
|  | Grade 1 | 0 | 3 ( 12.0) | 1 ( 3.8) | 1 ( 33.3) | 0 | 0 | 0 | 5 ( 3.9) |
|  | Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 ( 3.8) | 1 ( 0.8) |
|  | Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Missing | 0 | 0 | 0 | 0 | 0 | 0 | 1 ( 3.8) | 1 ( 0.8) |
|  |
| Urea |  |  |  |  |  |  |  |  |  |
|  | Baseline |  |  |  |  |  |  |  |  |
|  | Grade 0 | 23 (100.0) | 24 ( 96.0) | 25 ( 96.2) | 3 (100.0) | 25 (100.0) | 3 (100.0) | 26 (100.0) | 129 ( 98.5) |
|  | Grade 1 | 0 | 1 ( 4.0) | 1 ( 3.8) | 0 | 0 | 0 | 0 | 2 ( 1.5) |
|  | Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Day 7 |  |  |  |  |  |  |  |  |
|  | Grade 0 | 23 (100.0) | 25 (100.0) | 26 (100.0) | 2 ( 66.7) | 23 ( 92.0) | 3 (100.0) | 25 ( 96.2) | 127 ( 96.9) |
|  | Grade 1 | 0 | 0 | 0 | 1 ( 33.3) | 2 ( 8.0) | 0 | 1 ( 3.8) | 4 ( 3.1) |
|  | Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Day 21 |  |  |  |  |  |  |  |  |
|  | Grade 0 | 21 (100.0) | 25 (100.0) | 25 ( 96.2) | 3 (100.0) | 22 ( 91.7) | 3 (100.0) | 26 (100.0) | 125 ( 97.7) |
|  | Grade 1 | 0 | 0 | 1 ( 3.8) | 0 | 1 ( 4.2) | 0 | 0 | 2 ( 1.6) |
|  | Grade 2 | 0 | 0 | 0 | 0 | 1 ( 4.2) | 0 | 0 | 1 ( 0.8) |
|  | Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Day 28 |  |  |  |  |  |  |  |  |
|  | Grade 0 | 21 (100.0) | 25 (100.0) | 26 (100.0) | 3 (100.0) | 24 ( 96.0) | 2 ( 66.7) | 26 (100.0) | 127 ( 98.4) |
|  | Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Grade 2 | 0 | 0 | 0 | 0 | 1 ( 4.0) | 1 ( 33.3) | 0 | 2 ( 1.6) |
|  | Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  | Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

\* CS denotes Group C sentinel participants, DS Group D sentinel participants, N number of participants assessed.

† Group A (placebo): 0 µg NVX-CoV2373/0 µg Matrix-M1 on first vaccination; 0 µg NVX-CoV2373/0 µg Matrix-M1 on second vaccination; Group B: 25 µg NVX-CoV2373/0 µg Matrix-M1 on first vaccination; 25 µg NVX-CoV2373/0 µg Matrix-M1 on second vaccination; Group C/CS: 5 µg NVX-CoV2373/50 µg Matrix-M1 on first vaccination; 5 µg NVX-CoV2373/50 µg Matrix-M1 on second vaccination; Group D/DS: 25 µg NVX-CoV2373/50 µg Matrix-M1 on first vaccination; 25 µg NVX-CoV2373/50 µg Matrix-M1 on second vaccination; and Group E: 25 µg NVX-CoV2373/50 µg Matrix-M1 on first vaccination; 0 µg NVX-CoV2373/0 µg Matrix-M1 on second vaccination.

| Table S9. Treatment-emergent adverse events by system organ class and preferred term reported in 1% or more participants in the total group.\* |
| --- |
| **Group**AGEU | **A** | **B** | **C** | **C-Sentinel** | **D** | **D-Sentinel** | **E** | **Total****131** |
| **NVX-CoV2373 Dose 1/2 (µg)** | **0/0** | **25/25** | **5/5** | **5/5** | **25/25** | **25/25** | **25/0** |
| **Matrix-M1 Dose 1/2 (µg)** | **0/0** | **0/0** | **50/50** | **50/50** | **50/50** | **50/50** | **50/0** |
| **System Organ Class/Preferred Term† N** | **23** | **25** | **26** | **3** | **25** | **3** | **26** |
| Any TEAE‡ | 7 ( 30.4) | 11 ( 44.0) | 12 ( 46.2) | 1 ( 33.3) | 10 ( 40.0) | 2 ( 66.7) | 11 ( 42.3) | 54 ( 41.2) |
| General disorders and administration site conditions | 2 ( 8.7) | 5 ( 20.0) | 2 ( 7.7) | 0 | 1 ( 4.0) | 0 | 4 ( 15.4) | 14 ( 10.7) |
| Catheter site bruise | 0 | 0 | 1 ( 3.8) | 0 | 1 ( 4.0) | 0 | 0 | 2 ( 1.5) |
| Catheter site pain | 1 ( 4.3) | 1 ( 4.0) | 0 | 0 | 0 | 0 | 0 | 2 ( 1.5) |
| Fatigue | 1 ( 4.3) | 0 | 0 | 0 | 0 | 0 | 1 ( 3.8) | 2 ( 1.5) |
| Injection site bruising | 0 | 1 ( 4.0) | 0 | 0 | 0 | 0 | 1 ( 3.8) | 2 ( 1.5) |
| Infections and infestations | 1 ( 4.3) | 2 ( 8.0) | 4 ( 15.4) | 0 | 2 ( 8.0) | 0 | 3 ( 11.5) | 12 ( 9.2) |
| Upper respiratory tract infection | 0 | 0 | 3 ( 11.5) | 0 | 1 ( 4.0) | 0 | 0 | 4 ( 3.1) |
| Nervous system disorders | 2 ( 8.7) | 1 ( 4.0) | 2 ( 7.7) | 0 | 2 ( 8.0) | 0 | 1 ( 3.8) | 8 ( 6.1) |
| Headache | 1 ( 4.3) | 1 ( 4.0) | 1 ( 3.8) | 0 | 0 | 0 | 0 | 3 ( 2.3) |
| Musculoskeletal and connective tissue disorders | 0 | 1 ( 4.0) | 1 ( 3.8) | 0 | 3 ( 12.0) | 1 ( 33.3) | 1 ( 3.8) | 7 ( 5.3) |
| Arthralgia | 0 | 0 | 1 ( 3.8) | 0 | 1 ( 4.0) | 0 | 0 | 2 ( 1.5) |
| Respiratory, thoracic and mediastinal disorders | 0 | 4 ( 16.0) | 0 | 0 | 0 | 0 | 3 ( 11.5) | 7 ( 5.3) |
| Oropharyngeal pain | 0 | 1 ( 4.0) | 0 | 0 | 0 | 0 | 1 ( 3.8) | 2 ( 1.5) |
| Investigations | 0 | 1 ( 4.0) | 2 ( 7.7) | 1 ( 33.3) | 0 | 0 | 2 ( 7.7) | 6 ( 4.6) |
| Haemoglobin decreased | 0 | 1 ( 4.0) | 1 ( 3.8) | 1 ( 33.3) | 0 | 0 | 2 ( 7.7) | 5 ( 3.8) |
| Injury, poisoning and procedural complications | 1 ( 4.3) | 2 ( 8.0) | 0 | 0 | 0 | 0 | 2 ( 7.7) | 5 ( 3.8) |
| Muscle strain | 0 | 1 ( 4.0) | 0 | 0 | 0 | 0 | 1 ( 3.8) | 2 ( 1.5) |
| Skin and subcutaneous tissue disorders | 0 | 0 | 1 ( 3.8) | 0 | 1 ( 4.0) | 1 ( 33.3) | 2 ( 7.7) | 5 ( 3.8) |
| Rash | 0 | 0 | 0 | 0 | 1 ( 4.0) | 1 ( 33.3) | 0 | 2 ( 1.5) |
| Gastrointestinal disorders | 1 ( 4.3) | 1 ( 4.0) | 1 ( 3.8) | 0 | 0 | 0 | 1 ( 3.8) | 4 ( 3.1) |
| Eye disorders | 0 | 0 | 0 | 0 | 1 ( 4.0) | 0 | 1 ( 3.8) | 2 ( 1.5) |
| Psychiatric disorders | 1 ( 4.3) | 0 | 0 | 0 | 1 ( 4.0) | 0 | 0 | 2 ( 1.5) |

\* TEAE denotes treatment-emergent adverse event.

† Adverse events were coded using MedDRA Version 23.0.

‡ Based on all TEAEs.

| Table S10. Geometric mean titer IgG responses to NVX-CoV2373 with or without Matrix-M1 adjuvant in participants and compared to cconvalescent serum specimens. |
| --- |
| **Vaccine Group** | **Group A** | **Group B** | **Group C** | **Group D** | **Group E** | **Groups D + E** | **Convalescent Serum****(N=29)** |
| **NVX-CoV2373 Dose 1/2 (µg)**  | **0/0** | **25/25** | **5/5** | **25/25** | **25/0** |
| **Matrix-M1 Dose 1/2 (µg)** | **0/0** | **0/0** | **50/50** | **50/50** | **50/0** |
| **IgG ELISA anti-S protein (GMEUs)** |  |  |  |  |  |  |  |
| Day 0 |  |  |  |  |  |  |  |
| N\* | 23 | 25 | 29 | 28 | 26 | 54 |  |
| GMT | 108.5 | 115.6 | 113.6 | 114.3 | 104.9 | 109.6 |  |
| 95% CI† | (91.6, 128.4) | (97.5, 137.1) | (97.8, 132.0) | (92.8, 140.7) | (95.1, 115.6) | (97.8, 122.9) |  |
| Day 7 |  |  |  |  |  |  |  |
| N\* | 23 | 25 | 29 | 28 | 26 | 54 |  |
| GMT | 110.4 | 122.7 | 131.8 | 160.5 | 180.8 | 169.9 |  |
| 95% CI† | (89.9, 135.7) | (100.5, 149.8) | (107.6, 161.4) | (113.0, 227.8) | (122.0, 267.8) | (131.8, 219.1) |  |
| GMFR referencing Day 0 | 1.0 | 1.1 | 1.2 | 1.4 | 1.7 | 1.6 |  |
| 95% CI† | (1.0, 1.1) | (1.0, 1.2) | (1.0, 1.4) | (1.1, 1.8) | (1.2, 2.5) | (1.2, 1.9) |  |
| SCR ≥ 4-fold increase, n2/n1 (%)‡ | 0/23 (0.0%) | 0/25 (0.0%) | 1/29 (3.4%) | 1/28 (3.6%) | 4/26 (15.4%) | 5/54 (9.3%) |  |
| 95% CI | (0.0, 14.8) | (0.0, 13.7) | (0.1, 17.8) | (0.1, 18.3) | (4.4, 34.9) | (3.1, 20.3) |  |
| SRR ≥ 95th percentile, n2/n1 (%)‡§ | 1/23 (4.3%) | 2/25 (8.0%) | 2/29 (6.9%) | 4/28 (14.3%) | 6/26 (23.1%) | 10/54 (18.5%) |  |
| 95% CI | (0.1, 21.9) | (1.0, 26.0) | (0.8, 22.8) | (4.0, 32.7) | (9.0, 43.6) | (9.3, 31.4) |  |
| Day 21 |  |  |  |  |  |  |  |
| N\* | 21 | 25 | 29 | 27 | 26 | 53 |  |
| GMT | 109.7 | 189.2 | 1984.2 | 2625.9 | 3317.2 | 2944.8 |  |
| 95% CI† | (90.4, 133.2) | (117.6, 304.5) | (1405.8, 2800.7) | (1579.4, 4365.6) | (2202.4, 4996.2) | (2141.9, 4048.7) |  |
| GMFR referencing Day 0 | 1.0 | 1.6 | 17.5 | 22.9 | 31.6 | 26.8 |  |
| 95% CI† | (1.0, 1.0) | (1.0, 2.6) | (11.7, 26.1) | (13.0, 40.1) | (20.4, 49.0) | (18.9, 38.0) |  |
| SCR ≥ 4-fold increase, n2/n1 (%)‡ | 0/21 (0.0%) | 3/25 (12.0%) | 26/29 (89.7%) | 25/27 (92.6%) | 25/26 (96.2%) | 50/53 (94.3%) |  |
| 95% CI | (0.0, 16.1) | (2.5, 31.2) | (72.6, 97.8) | (75.7, 99.1) | (80.4, 99.9) | (84.3, 98.8) |  |
| SRR ≥ 95th percentile, n2/n1 (%)‡§ | 1/21 (4.8%) | 6/25 (24.0%) | 27/29 (93.1%) | 25/27 (92.6%) | 26/26 (100.0%) | 51/53 (96.2%) |  |
| 95% CI | (0.1, 23.8) | (9.4, 45.1) | (77.2, 99.2) | (75.7, 99.1) | (86.8, 100.0) | (87.0, 99.5) |  |
| Day 28 |  |  |  |  |  |  |  |
| N\* | 21 | 25 | 29 | 27 | 26 | --- |  |
| GMT | 110.6 | 206.9 | 15318.8 | 20429.2 | 3503.2 | --- |  |
| 95% CI† | (89.7, 136.3) | (138.9, 308.1) | (9486.8, 24736.0) | (11974.4, 34853.6) | (2378.4, 5160.1) | --- |  |
| GMFR referencing Day 0 | 1.0 | 1.8 | 134.9 | 177.9 | 33.4 | --- |  |
| 95% CI† | (1.0, 1.0) | (1.2, 2.6) | (76.5, 237.8) | (103.0, 307.3) | (22.1, 50.4) | --- |  |
| SCR ≥ 4-fold increase, n2/n1 (%)‡ | 0/21 (0.0%) | 4/25 (16.0%) | 28/29 (96.6%) | 26/27 (96.3%) | 26/26 (100.0%) | --- |  |
| 95% CI | (0.0, 16.1) | (4.5, 36.1) | (82.2, 99.9) | (81.0, 99.9) | (86.8, 100.0) | --- |  |
| SRR ≥ 95th percentile, n2/n1 (%)‡§ | 1/21 (4.8%) | 6/25 (24.0%) | 29/29 (100.0%) | 27/27 (100.0%) | 26/26 (100.0%) | --- |  |
| 95% CI | (0.1, 23.8) | (9.4, 45.1) | (88.1, 100.0) | (87.2, 100.0) | (86.8, 100.0) | --- |  |
| Day 35 |  |  |  |  |  |  | GMT:Overall (n=29): 8343.7(4420.9, 15747.5)Asymptomatic/Exposed (n=3): 1661.1Outpatient (n=22): 7419.6Hospitalized (n=4): 53391.3 |
| N\* | 21 | 25 | 29 | 27 | 26 | --- |
| GMT | 113.5 | 575.5 | 63160.4 | 47521.0 | 2932.0 | --- |
| 95% CI† | (93.6, 137.6) | (331.7, 998.5) | (47117.3, 84666.0) | (33803.7, 66804.6) | (1987.7, 4324.8) | --- |
| GMFR referencing Day 0 | 1.0 | 5.0 | 556.0 | 413.8 | 28.0 | --- |
| 95% CI† | (0.9, 1.1) | (3.0, 8.3) | (389.1, 794.6) | (289.4, 591.8) | (18.4, 42.5) | --- |
| SCR ≥ 4-fold increase, n2/n1 (%)‡ | 0/21 (0.0%) | 15/25 (60.0%) | 29/29 (100.0%) | 27/27 (100.0%) | 25/26 (96.2%) | --- |
| 95% CI | (0.0, 16.1) | (38.7, 78.9) | (88.1, 100.0) | (87.2, 100.0) | (80.4, 99.9) | --- |
| SRR ≥ 95th percentile, n2/n1 (%)‡§ | 1/21 (4.8%) | 16/25 (64.0%) | 29/29 (100.0%) | 27/27 (100.0%) | 26/26 (100.0%) | --- |
| 95% CI | (0.1, 23.8) | (42.5, 82.0) | (88.1, 100.0) | (87.2, 100.0) | (86.8, 100.0) | --- |

CI denotes confidence interval, ELISA enzyme-linked immunosorbent assay, GMEU geometric mean ELISA units, GMFR geometric mean fold rise, GMT geometric mean titer, IgG immunoglobulin G, N number of subjects in the Per‑Protocol Analysis Set within each visit with non-missing data, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2, SCR seroconversion rate, SRR seroresponse rate.

\* The Per-Protocol Analysis Set was determined for each study visit and included all subjects who received at least one dose of study vaccine (SARS-CoV-2 rS or placebo), had at least a baseline and one serum sample IgG result available after vaccination, had no major protocol violations that impacted immunogenicity response at the corresponding study visit, and did not have a confirmed SARS-CoV-2 infection that was assessed to have started prior to the visit.

† The 95% CI for GMT and GMFR were calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation.

‡ Percentages for SCR and SRR were calculated as (n2/n1)\*100; where n1 = number of subjects in the Per-Protocol Set within each visit with non-missing data, and n2 = number of subjects who reported the event. The 95% CI for SCR and SRR were calculated using the exact Clopper-Pearson method.

§ The 95th Percentile was calculated from the associated baseline value of all subjects (across vaccine groups).

| Table S11. Geometric mean titer neutralizing antibody responses to NVX-CoV2373 with or without Matrix-M1 adjuvant in participants and compared to convalescent serum specimens. |
| --- |
| **Vaccine Group** | **Group A** | **Group B** | **Group C** | **Group D** | **Group E** | **Groups D + E** | **Convalescent Serum****(N=32)** |
| **NVX-CoV2373 Dose 1/2 (µg)**  | **0/0** | **25/25** | **5/5** | **25/25** | **25/0** |
| **Matrix-M1 Dose 1/2 (µg)** | **0/0** | **0/0** | **50/50** | **50/50** | **50/0** |
| **Neutralizing Antibody** |  |  |  |  |  |  |  |
| Day 0 |  |  |  |  |  |  |  |
| N\* | 23 | 25 | 29 | 28 | 26 | 54 |  |
| GMT | 20.0 | 20.0 | 20.0 | 20.0 | 20.0 | 20.0 |  |
| 95% CI† | (20.0, 20.0) | (20.0, 20.0) | (20.0, 20.0) | (20.0, 20.0) | (20.0, 20.0) | (20.0, 20.0) |  |
| Day 21 |  |  |  |  |  |  |  |
| N\* | 21 | 25 | 29 | 27 | 26 | 53 |  |
| GMT | 20.0 | 21.7 | 103.3 | 126.2 | 117.8 | 122.0 |  |
| 95% CI† | (20.0, 20.0) | (19.2, 24.6) | (74.8, 142.6) | (79.5, 200.4) | (74.2, 187.0) | (88.9, 167.3) |  |
| GMFR referencing Day 0 | 1.0 | 1.1 | 5.2 | 6.3 | 5.9 | 6.1 |  |
| 95% CI† | (1.0, 1.0) | (1.0, 1.2) | (3.7, 7.1) | (4.0, 10.0) | (3.7, 9.3) | (4.4, 8.4) |  |
| SCR ≥ 4-fold increase, n2/n1 (%)‡ | 0/21 (0.0%) | 1/25 (4.0%) | 21/29 (72.4%) | 20/27 (74.1%) | 17/26 (65.4%) | 37/53 (69.8%) |  |
| 95% CI | (0.0, 16.1) | (0.1, 20.4) | (52.8, 87.3) | (53.7, 88.9) | (44.3, 82.8) | (55.7, 81.7) |  |
| SRR ≥ 95th percentile, n2/n1 (%)‡§ | 0/21 (0.0%) | 2/25 (8.0%) | 26/29 (89.7%) | 23/27 (85.2%) | 24/26 (92.3%) | 47/53 (88.7%) |  |
| 95% CI | (0.0, 16.1) | (1.0, 26.0) | (72.6, 97.8) | (66.3, 95.8) | (74.9, 99.1) | (77.0, 95.7) |  |
| Day 35 |  |  |  |  |  |  | GMT:Overall (n=32): 983.8(579.4, 1670.5)Asymptomatic/exposed (n=3): 254.0Outpatient (n=25): 837.0Hospitalized (n=4): 7457.2 |
| N\* | 21 | 25 | 29 | 27 | 26 | --- |
| GMT | 20.0 | 41.4 | 3906.3 | 3305.0 | 127.6 | --- |
| 95% CI† | (20.0, 20.0) | (27.5, 62.4) | (2555.9, 5970.0) | (2205.3, 4953.2) | (81.8, 199.1) | --- |
| GMFR referencing Day 0 | 1.0 | 2.1 | 195.3 | 165.3 | 6.4 | --- |
| 95% CI† | (1.0, 1.0) | (1.4, 3.1) | (127.8, 298.5) | (110.3, 247.7) | (4.1, 10.0) | --- |
| SCR ≥ 4-fold increase, n2/n1 (%)‡ | 0/21 (0.0%) | 7/25 (28.0%) | 29/29 (100.0%) | 27/27 (100.0%) | 19/26 (73.1%) | --- |
| 95% CI | (0.0, 16.1) | (12.1, 49.4) | (88.1, 100.0) | (87.2, 100.0) | (52.2, 88.4) | --- |
| SRR ≥ 95th percentile, n2/n1 (%)‡§ | 0/21 (0.0%) | 13/25 (52.0%) | 29/29 (100.0%) | 27/27 (100.0%) | 23/26 (88.5%) | --- |
| 95% CI | (0.0, 16.1) | (31.3, 72.2) | (88.1, 100.0) | (87.2, 100.0) | (69.8, 97.6) | --- |

CI denotes confidence interval, GMFR geometric mean fold rise, GMT geometric mean titer, IgG immunoglobulin G, N number of subjects in the Per‑Protocol Analysis Set within each visit with non-missing data, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2, SCR seroconversion rate, SRR seroresponse rate.

\* The Per-Protocol Analysis Set was determined for each study visit and included all subjects who received at least one dose of study vaccine (SARS-CoV-2 rS or placebo), had at least a baseline and one serum sample IgG result available after vaccination, had no major protocol violations that impacted immunogenicity response at the corresponding study visit, and did not have a confirmed SARS-CoV-2 infection that was assessed to have started prior to the visit.

† The 95% CI for GMT and GMFR were calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation.

‡ Percentages for SCR and SRR were calculated as (n2/n1)\*100; where n1 = number of subjects in the Per-Protocol Set within each visit with non-missing data, and n2 = number of subjects who reported the event. The 95% CI for SCR and SRR were calculated using the exact Clopper-Pearson method.

§ The 95th Percentile was calculated from the associated baseline value of all subjects (across vaccine groups).

**References**

1. Buchholz UJ, Bukreyev A, Yang L, et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci U S A 2004;101:9804-9.

2. Sui J, Li W, Murakami A, et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci U S A 2004;101:2536-41.

3. Amanat F, White KM, Miorin L, et al. An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening. Curr Protoc Microbiol 2020;58:e108.

4. Food and Drug Administration CfBEaRU. Guidance for industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. In: (DHHS) DoHaHS, ed.September 2007.

5. D2.3 Priority List of Adverse Events of Special Interest: COVID-19. 2020. (Accessed June 19, 2020, at <https://brightoncollaboration.us/wp-content/uploads/2020/06/SPEAC_D2.3_V2.0_COVID-19_20200525_public.pdf>.)

6. Division of AIDS (DAIDS) NIoAaID, National Institutes of Health. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events. In: Services UDoHaH, ed.July 2017.